Antigen, Epitope, Or Other Immunospecific Immunoeffector (e.g., Immunospecific Vaccine, Immunospecific Stimulator Of Cell-mediated Immunity, Immunospecific Tolerogen, Immunospecific Immunosuppressor, Etc.) Patents (Class 424/184.1)
  • Patent number: 11944647
    Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.
    Type: Grant
    Filed: June 22, 2022
    Date of Patent: April 2, 2024
    Assignee: Juno Therapeutics, Inc.
    Inventors: Tina Albertson, Brian Christin, Jacob Randolph Garcia, Christopher Glen Ramsborg, Claire L. Sutherland, Clinton Weber, Rachel K. Yost, Mark J. Gilbert, He Li
  • Patent number: 11944672
    Abstract: The gist of the invention consists in the therapeutic vaccine for treatment of diabetes type 1 in children, which contains Treg cells CD3(+)CD4(+)CD25(high)CD127(?). Claimed too is the cell sorter used to produce the vaccine and the method of multiplying Treg cells in vitro.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: April 2, 2024
    Assignee: Gdanski Uniwersytet Medyczny
    Inventors: Piotr Trzonkowski, Malgorzata Mysliwiec, Natalia Marek-Trzonkowska
  • Patent number: 11912744
    Abstract: This disclosure describes compositions and methods involved in tumor suppression and inhibiting infection of cells by pathogens. Generally, the compositions include an mRNA cargo that can provide a therapeutic benefit after being introduced into an epithelial cell. In some cases, the mRNA can encode a polypeptide. In some cases, the polypeptide can suppress epithelial cell proliferation. In other embodiments, the polypeptide can be involved in innate immunity. In various embodiments, the polypeptide can include cathelicin antimicrobial protein (CAMP), calprotectin, S100A8, S100A9, a ?-defensin, S100A7, secretory leukocyte inhibitor, lipocalin 2, or lysozyme. In some embodiments, the mRNA can include a stabilizing moiety such as, for example, a 5? cap or a 3? extension.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: February 27, 2024
    Assignee: Antibiotic Alternatives LLC
    Inventors: Mark C. Herzberg, Karen Farnie Ross, Brent S. Sorenson
  • Patent number: 11892452
    Abstract: The present disclosure provides synthetic antibodies specific for a disease-associated antigen, and methods of using the antibodies in disease therapy. The present disclosure further provides diagnostic assays involving detecting the presence and/or level in biological sample of an antibody specific for a disease-associated antigen.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: February 6, 2024
    Assignee: The Regents of the University of California
    Inventors: Lawrence H. Fong, Serena Kwek MacPhee
  • Patent number: 11833118
    Abstract: A method of manufacturing a flowable and dispersible powder includes solubilizing a lipophilic substance in a terpene to form a mixture and treating the mixture to form a nanoemulsion dispersed in an aqueous solution. The aqueous solution includes at least one functional excipient. The nanoemulsion is then spray dried, thereby evaporating first the aqueous portion and then the terpene to form a dry powder formed from solid particles comprising the lipophilic substance.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: December 5, 2023
    Inventors: Andrew John Boeckl, David Edward Cookson
  • Patent number: 11793894
    Abstract: The present technology comprises methods for regulating an the immune system, and in particular methods for the regulation of a specific immune response, including the regulation of lymphocyte activity. Methods of the present technology comprise both the negative and positive modulation of CEACAM1 protein function.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: October 24, 2023
    Inventor: Gal Markel
  • Patent number: 11793869
    Abstract: The present invention is directed to improved methods of Enterovirus inactivation by formaldehyde in presence of tromethamine buffer resulting in maximum recovery of D-antigen. Subsequent adsorption of said sIPV on aluminium hydroxide provides significantly dose reduced sIPV compositions.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: October 24, 2023
    Assignee: Serum Institute Of India Pvt Ltd.
    Inventors: Rajeev Mhalasakant Dhere, Sambhaji Shankar Pisal, Jagdish Kamalaji Zade, Rajendra Narayan Sabale, Hitesh Kumar Malviya, Sunil Mahor, Chetan Vilasrao Joshi
  • Patent number: 11771757
    Abstract: Disclosed is a stable immunogenic composition capable of eliciting a robust and durable immune response, comprising at least one antigen consisting of a filovirus glycoprotein and at least one nano-emulsion adjuvant which are co-lyophilized and can be reconstituted immediately prior to use. Also disclosed is a vaccine composition comprising at least two antigens, wherein each antigen is specific to a different genus of filovirus and which also comprises at least one nano-emulsion adjuvant.
    Type: Grant
    Filed: September 2, 2022
    Date of Patent: October 3, 2023
    Assignees: Soligenix, Inc., University of Hawaii
    Inventors: Oreola Donini, Axel Lehrer
  • Patent number: 11759347
    Abstract: An apparatus used for increasing the level of CD4+T cells in a mammal. The mammal has a cancerous tissue. The apparatus comprises a cold treatment unit and a heat treatment unit. The cold treatment unit is used for cooling the cancerous tissue. The heat treatment unit is used for heating the cancerous tissue. A method for increasing the level of CD4+ T cells in the body of a cancer patient, comprising steps for cold treatment of the cancerous tissue and for heat treatment of the cancerous tissue.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: September 19, 2023
    Inventors: Xuemin Xu, Aili Zhang, Ping Liu, Jingfeng Bai, Jianqi Sun
  • Patent number: 11744856
    Abstract: Pharmaceutical and cosmetic compositions and methods are presented that have a carrier in combination with a media composition that is derived from distinct cell cultures. The distinct cell cultures are obtained from growing different cells that are distinct with respect to at least one of cell type, cell age, cell differentiation stage, and physiological condition. Thus, the composite medium will provide mediator molecules that are ordinarily not founds in their combination and that can be fine tuned to specific purposes.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: September 5, 2023
    Assignee: MediCell Technologies, LLC
    Inventors: Nikolay Turovets, Christopher B. Adams
  • Patent number: 11666548
    Abstract: The present disclosure relates to parenteral nutrition formulations, including ready-to-use parenteral nutrition formulations which are reconstituted from multi-chamber containers and amino acid formulations. More particularly, the present disclosure is directed to formulations comprising butyrate derivatives, specifically arginine butyrate, for use with adult or pediatric patients. The disclosure further provides for methods of reducing or preventing systemic and local inflammation of patients receiving parenteral nutrition, and methods of maintaining or ameliorating their systemic immunity and local immunity, as well as the patients' gut barrier functions.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: June 6, 2023
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Laurent Christian Jeannin, Mary Hise Brown, Julien Andre Roger Hecq, Gary P. Zaloga, Kelly Tappenden
  • Patent number: 11649293
    Abstract: The present invention provides methods for producing antibodies against peptides, proteins, or such to which immune tolerance is easily established, by using antigen-binding molecules comprising a domain that binds to a molecule expressed on the surface of a cell having an immune response-suppressing function and a T cell receptor (TCR) complex-binding domain. The present invention also provides pharmaceutical compositions for use in combination with therapeutic vaccines and agents for enhancing a humoral immune response, each comprising the antigen-binding molecules as active ingredients.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: May 16, 2023
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventor: Tomoyuki Igawa
  • Patent number: 11642399
    Abstract: The invention provides methods for producing soluble di-chain BoNT/A protein.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: May 9, 2023
    Inventors: Shilpa Palan, Sai Man Liu, Gavin Stephen Hackett
  • Patent number: 11633422
    Abstract: Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.
    Type: Grant
    Filed: September 7, 2015
    Date of Patent: April 25, 2023
    Assignee: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto
  • Patent number: 11628215
    Abstract: Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: April 18, 2023
    Assignees: Vir Biotechnology, Inc., Triad National Security, LLC, Oregon Health & Science University
    Inventors: Eric Bruening, Klaus Frueh, Louis Picker, Bette T. M. Korber, James Theiler, Emily Marshall
  • Patent number: 11612586
    Abstract: The disclosure provides methods and compositions for affecting the development of antigen presenting cell (APC, e.g., a macrophage or dendritic cell). The methods include maturing an APC, promoting anti-inflammatory phenotype, promoting development of a T regulatory cell (Treg) from a naive T cell. The methods generally include exposing an APC to a tryptophan derived microbiota metabolite (TDMM), such as an anti-inflammatory or pro-mucosal TDMM, and permitting the APC to mature. In some embodiments, the conditioned APC is exposed to a naive T cell to further promote development of a T regulatory cell (Treg). In some embodiments, the TDMM is selected from the group consisting of indole, indole-3-acetate, 5-hydroxyindole, and indole-3-pyruvate.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: March 28, 2023
    Assignees: The Texas A&M University System, Trustees of Tufts College
    Inventors: Robert C. Alaniz, Arul Jayaraman, Kyongbum Lee
  • Patent number: 11612562
    Abstract: An objective of the present invention is to provide stable antibody-containing formulations which are suitable for subcutaneous administration and in which aggregation formation is suppressed during long-term storage. The present inventors discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid as a counter ion species in histidine buffer or tris(hydroxymethyl)aminomethane, specifically by using histidine-aspartate buffer or histidine-glutamate buffer, or tris(hydroxymethyl)aminomethane-aspartate or tris(hydroxymethyl)aminomethane-glutamate as a buffer. The present inventors also discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid, as a counter ion species to a basic amino acid such as arginine, specifically by using arginine-aspartate or arginine-glutamate.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: March 28, 2023
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Chifumi Moriyama
  • Patent number: 11603391
    Abstract: The present invention provides new derivatives of CATH2 or CMAP27, one of the cathelicidins. These derivatives comprise N-terminally truncated peptides, cyclic peptides, D-amino acid variants of CATH2 and its truncated derivatives, inverso and retroinverso CATH2 derivatives. These derivatives are useful as anti-infectives, in vaccines, and especially for in ovo applications. Further, for the above derivatives and also for the already known C-terminally truncated derivatives new immunoactivating functions have been described that are particularly advantageous for prophylactic treatments.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: March 14, 2023
    Assignee: Universiteit Utrecht Holding B.V.
    Inventors: Hendrik Peter Haagsman, Albert van Dijk, Edwin Johannes Adrianus Veldhuizen
  • Patent number: 11559567
    Abstract: A pegylated type I interferon for use in treating an infectious disease, cancer, or myeloproliferative disease in a subject in need thereof, wherein a 50 to 540 ?g dose of the pegylated type I interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: January 24, 2023
    Assignee: PharmaEssentia Corporation
    Inventors: Christoph Klade, Oleh Zagrijtschuk, Ko-Chung Lin
  • Patent number: 11548930
    Abstract: The present disclosure relates to, inter alia, a method for treating a tumor by intratumorally delivering an effective amount of a composition comprising an expression vector that comprises a first nucleotide sequence encoding a secretable vaccine protein, and a second nucleotide sequence encoding a T cell costimulatory fusion protein.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: January 10, 2023
    Assignee: Heat Biologics, Inc.
    Inventors: Suresh De Silva, Taylor Schreiber
  • Patent number: 11519008
    Abstract: This disclosure relates to the field of exosome delivery systems. In particular, compositions comprising adipose-derived exosomes that may be used as a delivery system are encompassed. The exosome delivery system can be used to deliver exogenous cargo such as miRNA and other inhibitory RNAs, as well as proteins, to target cells in a subject.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: December 6, 2022
    Assignee: Joslin Diabetes Center
    Inventors: C. Ronald Kahn, Thomas Thomou
  • Patent number: 11498942
    Abstract: The present invention is directed to an isolated synthetic tripeptide of formula H-D-Phe-N-Methyl-L-Val-L-Ala-OMe (SEQ ID NO:1), or a derivative thereof, and to the corresponding lipotripeptides, which are specific to Mycobacterium avium subsp. paratuberculosis (Map) S-type strain, as well as derivatives and conjugates thereof. The invention also concerns the use of these antigens in different methods and tests for detecting Map infection, especially by detecting humoral response and cell mediated response of infected animals. The invention is also directed to a genetic signature of Map and a mass spectrometry and NMR spectroscopy signature of Map presence or infection.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 15, 2022
    Inventors: John P. Bannantine, Gilles Etienne, Sylvie Bay, Franck Biet
  • Patent number: 11471495
    Abstract: The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: October 18, 2022
    Inventors: Eric Pamer, Charlie Buffie, Peter McKenney
  • Patent number: 11464840
    Abstract: The embodiment of the invention is to enable universal non-classical MHC I peptide vaccines restricted to HLA-E, HLA-F and HLA-G. An algorithm was develop to predict HLA-E binding immunogenic or suppressorgenic peptides of the autologous origins, e.g., autoantigens, inflammatory antigens, IgE and cancer antigens, and of the microbial origins. Thus, the embodiment of the invention is to load the antigenic peptides of medical and therapeutic importance onto the non-polymorphic HLA-E, HLA-F, and HLA-G culminating in universal vaccines, bypassing highly polymorphic classical MHC I, e.g., HLA-A, HLA-B and HLA-C pathways, in order to treat autoimmune diseases, allergy, inflammatory diseases, cancers, and infectious diseases for all human population. Derlin-1 and UL40 pathways are utilized to enable antigen presentation and vaccine efficacies in the non-classical MHC I pathways.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: October 11, 2022
    Inventor: Swey-Shen Chen
  • Patent number: 11466257
    Abstract: The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as ?-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: October 11, 2022
    Assignee: Seqirus UK Limited
    Inventors: Jens-Peter Gregersen, Holger Kost
  • Patent number: 11459390
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: October 4, 2022
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, David Glass, Thomas Huber, Julia Jascur, Carl H. June, Jihyun Lee, Joan Mannick, Michael C. Milone, Leon Murphy, Avery D. Posey, Huijuan Song, Yongqiang Wang, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Patent number: 11458196
    Abstract: The present invention relates to the composition and method of preparing an immunogen designated as I-spga consisting of a complex antigen prepared from 18 to 26 species of pathogenic microorganisms isolated from patients, inactivated with binary ethyleneamine (BEI) and formalin, diluted in a SPGA immunopotentiator mixed with QS-21 adjuvant. By inoculating the hens with the I-spga immunogen, hyperimmune eggs (Immunospga) are obtained which contain immunologically active proteins specific to the 18-26 antigens used for immunization. The immune response of the hens is specific to the used antigens by amplification of the antigenic signal by the SPGA immunopotentiator and due to a special immunization program that allows the immune system to act complex and intense: The I-spga complex antigen contains 18-26 microorganisms isolated from patients, bacterial bodies, components from bodies obtained by ultrasonography, cilia, exotoxins, endotoxins, spores, viruses, fungi or yeasts.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: October 4, 2022
    Inventors: Raul Sorin Fântân{hacek over (a)}, Claudiu Adrian Preda
  • Patent number: 11453867
    Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.
    Type: Grant
    Filed: October 19, 2021
    Date of Patent: September 27, 2022
    Inventors: David A. Scott, David R. Cheng, Winston X. Yan, Tia M. DiTommaso
  • Patent number: 11433129
    Abstract: Disclosed is a stable immunogenic composition capable of eliciting a robust and durable immune response, comprising at least one antigen consisting of a filovirus glycoprotein and at least one nano-emulsion adjuvant which are co-lyophilized and can be reconstituted immediately prior to use. Also disclosed is a vaccine composition comprising at least two antigens, wherein each antigen is specific to a different genus of filovirus and which also comprises at least one nano-emulsion adjuvant.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: September 6, 2022
    Assignees: Soligenix, Inc., University of Hawaii
    Inventors: Oreola Donini, Axel Lehrer
  • Patent number: 11433146
    Abstract: Provided herein are compositions and methods for generating an immunogenic response in humans. Further provided are methods for designing such compositions, e.g., for vaccines.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: September 6, 2022
    Assignee: Vaxart, Inc.
    Inventors: George Trager, Sean Tucker, Leesun Kim, Ciaran Scallan
  • Patent number: 11435356
    Abstract: Electrical detection methods are used to identify and further characterize single-molecule target analytes such as proteins and nucleic acids. A composition including a probe region and a tail region is contacted with a target analyte. The probe region specifically binds to the target analyte. The tail region is coupled to the probe region, and includes a nucleic acid template for polynucleotide synthesis. When conditions are such that polynucleotide synthesis occurs along the tail region, one hydrogen ion is released for every nucleotide that is incorporated into the tail region. A transistor such as an ISFET detects and measures changes in ion concentration, and these measurements can be used to identify the tail region and thus characterize the corresponding target analyte.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: September 6, 2022
    Inventors: Bryan P. Staker, Niandong Liu, Bart Lee Staker, Michael David McLaughlin
  • Patent number: 11434501
    Abstract: This invention relates to the prevention and treatment of neurodegenerative diseases by administering compositions that increase the activity of a small proline-rich repeat 1 A protein (Sprr1A), or derivative thereof to the brain. Specifically, the compositions may comprise a nucleic acid molecule encoding a Sprr1A protein or a biologically-active portion thereof. The neurodegenerative disease may be Parkinson's Disease, Alzheimer's disease, amyotrophic lateral sclerosis, or traumatic brain injury.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: September 6, 2022
    Assignee: Board of Trustees of Michigan State University
    Inventors: Jack W. Lipton, Nicholas Kanaan, Timothy Collier
  • Patent number: 11419928
    Abstract: Provided herein, in some embodiments, are methods and composition for treating cancer in a subject. The methods may include administering to the subject a nucleic acid encoding MIP3? fused to a cancer antigen, administering to the subject a CpG oligodeoxynucleotide, administering to the subject interferon alpha (IFN?), and administering to the subject 5-aza-2?-deoxycytidine (Aza), in effective amounts to treat the cancer.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: August 23, 2022
    Inventors: Richard Markham, James Gordy
  • Patent number: 11422127
    Abstract: Peripheral blood mononuclear cells (PBMCs) can be used in place of DCs when pulsing with antigens, or antigen and adjuvant combination, and then administered to a subject as a vaccine to induce a protective immune response. The PBMC-based vaccine strategy provides a more marked and enduring protective immune response and is also capable of serving as a multi-organism prophylactic vaccine platform. The vaccine platform may be used to screen vaccine and adjuvant combinations and may also be used to allow for adjuvants that are otherwise unsafe for use in humans as the adjuvant may be removed prior to prophylactic administration of the pulsed PBMCs.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: August 23, 2022
    Inventors: Edmund J. Gosselin, Sudeep Kumar, David Nalin
  • Patent number: 11421006
    Abstract: The invention provides Cockroach proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses and medicaments of such proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof. Such methods, uses and medicaments include modulating an immune response, protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease and inducing immunological tolerance to the allergen (e.g., Cockroach allergen) in a subject.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: August 23, 2022
    Inventors: Alessandro Sette, Bjoern Peters, Jason Greenbaum
  • Patent number: 11389518
    Abstract: Disclosed herein are Mycoplasma bovis immunogenic compositions useful in raising an immune response in animals against M. bovis. Also disclosed herein are methods for generating a protective response against infections in mammals caused by M. bovis.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: July 19, 2022
    Assignees: Zoetis Services LLC
    Inventors: Glenn Francis Browning, Philip Francis Markham, Marc Serge Marenda, Fred H. Weber, Suman Mahan
  • Patent number: 11389523
    Abstract: Methods of preparing influenza viruses having altered immunodominant epitopes in HA, e.g., having one or more residues in one or more of antigenic sites A-E in HA altered, and viral vectors, e.g., influenza virus VLPs or non-influenza viruses or VLPs thereof expressing or having influenza HAs with altered immunogenicity as a result of altered immunodominant epitopes therein are provided.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: July 19, 2022
    Assignee: Wisconsin Alumni Research Foundation (WARF)
    Inventors: Yoshihiro Kawaoka, Gabriele Neumann, Huihui Kong
  • Patent number: 11377645
    Abstract: Provided are Cas9 enzymes that have mutations that enhance their properties, relative to un-mutated Cas9. The altered Cas9 enzymes exhibit i) an increased rate of spacer acquisition, or ii) increased cleavage efficiency of targets with NAG PAMs, or a combination of i) and ii). The altered Cas9 enzymes comprise an amino acid substitution of 1473 and K500 in a Streptococcus pyogenes or similar Cas9 enzyme. Also provided are polynucleotides, including expression vectors that encode the Cas9 enzymes, cells that contain the polynucleotides, and methods of making and using such cells. The disclosure includes tagging, or labelling bacteria, and for enhancing phage acquired immunity in bacteria, such as those used in industrial processes, including the food and beverage industry, such as the dairy industry. The food products are also included.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: July 5, 2022
    Assignee: The Rockefeller University
    Inventors: Luciano Marraffini, Robert Heller, David Bikard
  • Patent number: 11370839
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind ILT3, ILT3 ligand (i.e., PI16) or a complex between ILT3 and the ILT3 ligand. Methods for determining whether ILT3 and the ILT3 ligand bind together or whether a substance agonizes or antagonizes such binding are also provided.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: June 28, 2022
    Inventors: Daniel Cua, Holly Cherwinski, Adele Wang, Yi Chen, Barbara Joyce-Shaikh
  • Patent number: 11360104
    Abstract: Described herein are methods, compositions and processes related to a microbial-based biosensor system for the detection of small molecules and analytes based on an analyte-responsive transcription factor-DNA binding mechanism with either a ratiometric fluorescent output through Förster resonance energy transfer (FRET) or a redox sensor output for the quantification of the target analyte with high sensitivity.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: June 14, 2022
    Inventors: James Galagan, Allison Dennis, Catherine Klapperich, Mark Grinstaff, Thuy Nguyen, R. Baer, Uros Kuzmanovic, Marjon Zamani, Mingfu Chen, Margaret Chern, Chloe Grazon
  • Patent number: 11359022
    Abstract: Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: June 14, 2022
    Assignee: Alpine Immune Sciences, Inc.
    Inventors: Ryan Swanson, Michael Kornacker
  • Patent number: 11351104
    Abstract: A colloidal dispersion is disclosed comprising poly alpha-1,3-glucan or poly alpha-1,3-1,6-glucan and a solvent. The colloidal dispersion has utility in various applications, including food, oil field, pharmaceutical, personal care and specialty industries.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: June 7, 2022
    Inventors: Ji Yeon Huh, Natnael Behabtu, Rakesh Nambiar
  • Patent number: 11351249
    Abstract: The invention relates generally to vaccine compositions that are capable of eliciting and sustaining an immune response in a subject. The vaccine composition comprises a water-in-oil emulsion and a plurality of immunogen loaded hydrogel particles surrounded with a cationic polymer shell dispersed in the aqueous phase of the emulsion.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: June 7, 2022
    Inventors: David E. Mainwaring, Mohammad Al Kobaisi
  • Patent number: 11344611
    Abstract: The present invention relates to tick polypeptides and compositions comprising the same, which are useful for treatment or prophylaxis of tick infestation in a subject.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: May 31, 2022
    Inventors: Alicja Tabor, Matthew Bellgard, Manuel Rodriguez Valle
  • Patent number: 11339437
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: May 24, 2022
    Inventors: Morgan Lee Maeder, Rina J. Mepani, David A. Bumcrot, Shen Shen, Michael Stefanidakis
  • Patent number: 11340224
    Abstract: Embodiments of this invention include methods for detecting in vitro the presence of Memory B cells in peripheral blood mononuclear cells (PBMCs) that produce antibodies reactive to CNS antigens associated with Multiple Sclerosis (MS). Stimulating PBMCs from patients with MS by a polyclonal stimulating agent promotes the ability of B-lymphocytes, when exposed to a CNS antigen, to produce antibodies specific for the CNS antigen. In contrast, stimulating PBMCs from subjects without MS do not produce such responses.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: May 24, 2022
    Inventors: Stefanie Kuerten, Paul Lehmann
  • Patent number: 11339409
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: May 24, 2022
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 11331352
    Abstract: The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: May 17, 2022
    Assignee: 4D Pharma Research Limited
    Inventors: George Grant, Angela Margaret Patterson, Imke Mulder, Seanin McCluskey, Emma Raftis
  • Patent number: 11324739
    Abstract: Novel combination therapies involving nitroxoline, its analogue or pharmaceutically acceptable salt thereof with at least one additional anti-cancer chemotherapy or immunotherapy agent are described. Related kits, pharmaceutical compositions and methods of production arlinee also described.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: May 10, 2022
    Assignee: Jiangsu Yahong Meditech Co., Ltd.
    Inventors: Ke Pan, Peng Huang, Qiang Li
  • Patent number: 11312953
    Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: April 26, 2022
    Assignee: Caribou Biosciences, Inc.
    Inventors: Andrew Paul May, Rachel E. Haurwitz, Jennifer A. Doudna, James M. Berger, Matthew Merrill Carter, Paul Daniel Donohoue